Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Emergency contraceptives

This article was originally published in The Tan Sheet

Executive Summary

Advance prescriptions would be first step to increasing access to Women's Capital Corp.' s Plan B and Gynetics' Preven and reducing unintended pregnancies, abortions, American College of Obstetricians & Gynecologists says April 30 at group's annual clinical meeting in Chicago. President-elect Thomas Purdon, MD, recommends change in current prescribing practices. Group also calls for eventual OTC switch of drugs; an NDA for Plan B is being prepared for submission this year or next (1"The Tan Sheet" Dec. 18, 2000, p. 3)

You may also be interested in...



Plan B Emergency Contraceptive Switch NDA Planned

Women's Capital Corporation will file an NDA next year to switch its Plan B emergency contraceptive to OTC status, the company said Dec. 13.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS092507

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel